Literature DB >> 29229596

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.

Rosemary E Gale1, Teodora Popa1, Melissa Wright2, Naeem Khan3, Sylvie D Freeman3, Alan K Burnett4, Nigel H Russell5, Robert K Hills2, David C Linch1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29229596     DOI： 10.1182/blood-2017-08-802157

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

1.  Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come.

Authors:  Johann Hitzler; Elihu Estey
Journal:  Haematologica       Date:  2019-01       Impact factor: 9.941

2.  Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.

Authors:  George S Laszlo; Mary E Beddoe; Colin D Godwin; Olivia M Bates; Chelsea J Gudgeon; Kimberly H Harrington; Roland B Walter
Journal:  Haematologica       Date:  2018-08-16       Impact factor: 9.941

Review 3.  Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.

Authors:  Jeffrey Baron; Eunice S Wang
Journal:  Expert Rev Clin Pharmacol       Date:  2018-06-11       Impact factor: 5.045

Review 4.  The clinical development of antibody-drug conjugates - lessons from leukaemia.

Authors:  Elias Jabbour; Shilpa Paul; Hagop Kantarjian
Journal:  Nat Rev Clin Oncol       Date:  2021-03-23       Impact factor: 66.675

5.  CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Authors:  Lata Chauhan; Miyoung Shin; Yi-Cheng Wang; Michael Loken; Jessica Pollard; Richard Aplenc; Betsy A Hirsch; Susana Raimondi; Rhonda E Ries; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi; Jatinder K Lamba
Journal:  JCO Precis Oncol       Date:  2019-05-23

6.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

7.  A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.

Authors:  Priyanka Nair-Gupta; Michael Diem; Dara Reeves; Weirong Wang; Robert Schulingkamp; Katrin Sproesser; Bethany Mattson; Bradley Heidrich; Mark Mendonça; Jocelin Joseph; Jocelyn Sendecki; Brad Foulk; Gerald Chu; Damien Fink; Qun Jiao; Sheng-Jiun Wu; Kathryn Packman; Yusri Elsayed; Ricardo Attar; François Gaudet
Journal:  Blood Adv       Date:  2020-03-10

Review 8.  The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia.

Authors:  Pamela C Egan; John L Reagan
Journal:  Onco Targets Ther       Date:  2018-11-22       Impact factor: 4.147

9.  A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.

Authors:  Dina Schneider; Ying Xiong; Peirong Hu; Darong Wu; Weizao Chen; Tianlei Ying; Zhongyu Zhu; Dimiter S Dimitrov; Boro Dropulic; Rimas J Orentas
Journal:  Front Oncol       Date:  2018-11-22       Impact factor: 6.244

10.  CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.

Authors:  Michele Stanchina; Alessandro Pastore; Sean Devlin; Christopher Famulare; Eytan Stein; Justin Taylor
Journal:  J Hematol Oncol       Date:  2019-08-22       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.